DiaMedica Therapeutics (DMAC) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 54.2% versus a gain of 15.0%. Over five years, DMAC leads with a +88.3% price change compared with -87.0% for RLMD. DiaMedica Therapeutics is the larger company by market cap ($408.2 million vs $330.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | RLMD |
|---|---|---|
| Share price | $7.57 | $3.10 |
| Market cap | $408.22M | $330.68M |
| 1-day change | -5.85% | -3.13% |
| YTD return | -4.90% | -35.82% |
| 1-year return | +15.05% | +54.23% |
| 5-year return | +88.31% | -86.99% |
| EPS (TTM) | $-0.72 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-32.77M | $-57.39M |
| 52-week high | $10.42 | $8.00 |
| 52-week low | $5.25 | $1.97 |
| Distance from 52-week high | -27.35% | -61.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +104.76% | +246.77% |
| Average volume | 182.81K | 1.30M |
| Shares outstanding | 53.93M | 106.67M |
| Employees | 35 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed DMAC by 39.2 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 17 employees
DMAC vs RLMD FAQ
Which is bigger, DiaMedica Therapeutics or Relmada Therapeutics?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $408.22M compared with $330.68M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, DMAC or RLMD?
RLMD returned +54.23% over the past 12 months, compared with +15.05% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.